#1 Clinical Trials Search in Europe

A study comparing 68Ga-FAPI-46 PET scan with standard 18F-FDG PET scan and brain MRI for staging in patients with newly diagnosed non-small cell lung cancer

2 1 1 1

What is this study about?

This study involves patients with non-small cell lung cancer, which is a type of lung cancer. The study will use two different imaging substances to take pictures of the inside of the body. One substance is called 68Ga-FAPI-46, which is the main substance being tested in this study. The other substance is fludeoxyglucose (18F), which is already commonly used in regular medical care. Both substances are given through a vein and help doctors see where cancer may be present in the body using special scanning machines. Patients in this study will also have a brain scan called an MRI, which uses magnetic fields to create detailed pictures of the brain.

The purpose of this study is to gather information that will help plan a larger study in the future. Researchers want to compare how well the new imaging substance 68Ga-FAPI-46 works compared to the standard method that uses fludeoxyglucose (18F) and brain MRI for finding cancer that has spread to other parts of the body in patients who have been newly diagnosed with non-small cell lung cancer. The study will look at how many cancer spots are found with each method and where these spots are located in the body.

During the study, patients will receive scans with both imaging substances. They will first have or will have already had a scan with fludeoxyglucose (18F) as part of their regular care. Within three weeks, they will also receive a scan using 68Ga-FAPI-46. If a brain MRI has not already been done, patients will also undergo this scan. Doctors will then compare the results from both types of scans to see if the new substance finds cancer spots that the standard method might miss, or if the standard method finds spots that the new substance does not detect.

1 Initial imaging scan

Your participation in the trial begins after your lung cancer diagnosis has been confirmed through a biopsy. At this stage, you will either need to undergo a standard 18F-FDG PET/CT scan for diagnostic evaluation, or you may have already completed this scan.

The 18F-FDG PET/CT scan is an imaging procedure that uses a radioactive tracer called fludeoxyglucose combined with a computed tomography scan. This tracer is injected into your vein and helps to identify areas of increased metabolic activity, which may indicate cancer. The scan provides detailed images of your body to assess the extent of the disease.

If you have not yet had this scan, it will be performed as part of your standard diagnostic process.

2 Brain imaging assessment

You will undergo a brain MRI scan if this has not already been performed or scheduled as part of your regular care.

The MRI scan uses magnetic fields and radio waves to create detailed images of your brain. This scan helps to detect whether the cancer has spread to the brain.

This imaging procedure is part of the current standard approach to evaluate your condition.

3 Additional imaging with experimental tracer

Within three weeks after your 18F-FDG PET/CT scan, you will undergo an additional imaging scan called a 68Ga-FAPI-46 PET scan with a low-dose CT.

For this scan, you will receive an injection of a radioactive tracer called 68Ga-FAPI-46. This substance is administered as an intravenous bolus, which means it is injected directly into your vein as a single dose.

The 68Ga-FAPI-46 tracer works differently from the standard tracer. It targets specific proteins associated with cancer tissue, which may help to identify cancer spread in different ways than the standard scan.

The low-dose CT component provides anatomical images with reduced radiation exposure compared to a standard CT scan.

This additional scan is the investigational part of the trial and is performed to compare its effectiveness with the standard imaging methods.

4 Comparison of imaging results

After all imaging scans are completed, the results from the 68Ga-FAPI-46 PET scan will be compared with the results from your 18F-FDG PET/CT scan and brain MRI.

The comparison will assess whether the experimental scan detects cancer spread that was not visible on the standard scans, or whether the standard scans show findings not visible on the experimental scan.

If the 68Ga-FAPI-46 PET scan reveals findings that were not seen on the standard scans, additional clinical investigations may be necessary to clarify these findings.

The information gathered will help determine whether the experimental imaging method could be useful for future patients with lung cancer.

Who Can Join the Study?

  • You must have non-small cell lung cancer that has been confirmed by a biopsy, which is a procedure where a small sample of tissue is removed and examined under a microscope to check for cancer cells
  • You need to either require a special imaging scan called 18F-FDG PET/CT, which is a test that uses a small amount of radioactive sugar to find cancer in the body, or you must have already had this scan done
  • You must be at least 18 years old
  • Your ability to perform daily activities must be rated as ECOG score 0-2, which means you are either fully active, able to do light work, or capable of self-care but unable to work
  • You must be able to have another imaging scan called 68Ga-FAPI-46 PET with low dose CT within three weeks after your first scan
  • You must be willing and able to have a brain MRI, which is a scan that uses magnets and radio waves to create detailed pictures of your brain, if you have not already had one or do not have one scheduled as part of your regular care
  • You must be willing to sign and date a written informed consent form, which is a document that explains the study and confirms you agree to participate

Who Cannot Join the Study?

  • The study data does not provide specific reasons why patients cannot participate in this clinical trial
  • If you are considering joining a clinical trial, the research team will review your individual medical situation to determine if you are eligible
  • General factors that often prevent participation in cancer studies may include other serious medical conditions, previous treatments, or medications that could interfere with the study procedures
  • Pregnancy or breastfeeding (feeding a baby with breast milk) may also be reasons for exclusion in studies involving imaging procedures
  • The ability to undergo PET scans (special imaging tests that show how organs and tissues are working) and MRI (magnetic resonance imaging, a test that uses magnets and radio waves to create pictures of the inside of your body) may be required

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
University Hospital Maastricht Maastricht The Netherlands

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Not yet recruiting
02.02.2026

Trial locations

Investigated drugs:

68Ga-FAPI-46 is an imaging agent used during a PET scan to help doctors see cancer cells more clearly in the body. This medication contains a radioactive substance that attaches to certain proteins found on cancer cells, making them visible on special imaging equipment. It is being tested to see if it can provide better images than standard scanning methods for detecting and staging lung cancer.

18F-FDG is a radioactive sugar solution used as a standard imaging agent for PET scans. Cancer cells absorb this sugar more quickly than normal cells because they use more energy, which helps doctors locate tumors and see how far cancer has spread in the body. This is the current standard method used for imaging in lung cancer patients.

Investigated diseases:

Non-small cell lung cancer – Non-small cell lung cancer is a type of cancer that begins in the lungs and is the most common form of lung cancer. The disease occurs when cells in the lung tissue start to grow abnormally and uncontrollably, forming tumors. As the cancer progresses, it can spread beyond the lungs to other parts of the body, including the brain, bones, liver, and adrenal glands through a process called metastasis. The cancer cells can invade nearby tissues and enter the bloodstream or lymphatic system, allowing them to reach distant organs. Symptoms may develop gradually and can include persistent cough, chest pain, shortness of breath, and unexplained weight loss. The disease is classified into different stages based on the size of the tumor and how far it has spread throughout the body.

Trial ID:
2025-523032-39-00
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated drugs:
    France Germany Greece Italy The Netherlands Poland +1

  • Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain